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Cardiovascular disease is a leading cause of 
morbidity and mortality in the Western world. 
Dilated cardiomyopathy (DCM), often resulting 
from Coxsackievirus B3 and Chlamydia-trig-
gered myocarditis, may be present in up to one 
quarter of all cases of heart failure (1, 2). 
  Notably, many aff  ected individuals develop heart 
antigen–specifi  c autoantibody responses (3), 
and immunosuppressive therapy can improve 
heart function in DCM patients who display 
no evidence of viral or bacterial genomes in 
heart biopsies (4). Interestingly, peripheral 
blood lymphocytes from patients with DCM 
could adoptively transfer disease to SCID mice 
lacking T and B cells (5). These observations 
suggest that postinfectious autoimmune mech-
anisms promote disease development.
Experimental autoimmune myocarditis 
(EAM) is a mouse model of postinfectious 
myocarditis and cardiomyopathy (6). EAM can 
be induced in susceptible mouse strains by im-
munization with self-peptides derived from the 
myosin α heavy chain (MyHC-α). EAM is a 
CD4+ T cell–mediated disease (6–8), but the 
relative contributions of the CD4+ Th1 and 
Th2 subsets are unclear (9–13). The majority 
of infi  ltrating cells in EAM are macrophages, 
suggesting that Th1 signals predominate. Sig-
naling through the key Th2 cytokine IL-4 is 
dispensable for the development of EAM (10). 
Furthermore, the p40 subunit of the Th1-driv-
ing cytokine IL-12 and the β1 receptor subunit 
of the IL-12R are essential for disease progres-
sion (10, 11). However, in vivo IL-4 blockade 
has been shown to reduce disease severity (12). 
At the same time, loss of either IFN-γ or its 
  receptor results in increased disease severity, 
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Experimental autoimmune myocarditis (EAM) appears after infectious heart disease, the 
most common cause of dilated cardiomyopathy in humans. Here we report that mice lack-
ing T-bet, a T-box transcription factor required for T helper (Th)1 cell differentiation and 
interferon (IFN)-𝗄 production, develop severe autoimmune heart disease compared to 
T-bet+/+ control mice. Experiments in T-bet−/− IL-4−/− and T-bet−/− IL-4R𝗂−/− mice, as well 
as transfer of heart-specifi  c Th1 and Th2 cell lines, showed that autoimmune heart disease 
develops independently of Th1 or Th2 polarization. Analysis of T-bet−/− IL-12R𝗃1−/− and 
T-bet−/− IL-12p35−/− mice then identifi  ed interleukin (IL)-23 as critical for EAM patho-
genesis. In addition, T-bet−/− mice showed a marked increase in production of the IL-23–
dependent cytokine IL-17 by heart-infi  ltrating lymphocytes, and in vivo IL-17 depletion 
markedly reduced EAM severity in T-bet−/− mice. Heart-infi  ltrating T-bet+/+ CD8+ but not 
CD8− T cells secrete IFN-𝗄, which inhibits IL-17 production and protects against severe 
EAM. In contrast, T-bet−/− CD8+ lymphocytes completely lost their capacity to release IFN-𝗄 
within the heart. Collectively, these data show that severe IL-17–mediated EAM can 
  develop in the absence of T-bet, and that T-bet can regulate autoimmunity via the control 
of nonspecifi  c CD8+ T cell bystander functions in the infl  amed target organ.
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implying that this key Th1 cytokine is a negative regulator of 
EAM (10, 11, 13).
As IFN-γ signaling may not be absolutely required for 
the development of Th1 responses (14), we tested the disease 
susceptibility of mice lacking T-bet, a T-box transcription 
factor essential for Th1 lineage diff  erentiation (15, 16). T-bet−/− 
CD4+ T cells display a profound defect in IFN-γ production 
in vitro, and T-bet expression is critical for the development 
of infl  ammatory autoimmune diseases, such as experimental 
autoimmune encephalomyelitis, Crohn’s disease, type 1 dia-
betes, and atherosclerosis (17–21).
Here we show that in marked contrast to other autoim-
mune models, mice lacking T-bet develop severe EAM. 
MyHC-α–specifi  c CD4+ T cells trigger autoimmune myo-
carditis regardless of Th1 or Th2 commitment. Analysis of 
T-bet−/− IL-12Rβ1−/− and T-bet−/− IL-12p35−/− mice and 
antibody depletion experiments showed that IL-23 and IL-17 
are critical for EAM pathogenesis. Loss of T-bet results in in-
creased IL-17 production in the infl  amed heart, and this tis-
sue-specifi  c repression depends on CD8+ T cell–mediated 
bystander suppression. Our data indicate that T-bet expressed 
in the CD8+ T cell compartment is a negative regulator of 
autoimmune heart disease.
RESULTS
T-bet−/− mice develop severe myocarditis
IFN-γ production characterizes Th1 cells, and IFN-γ secreted 
from Th1 cells strongly activates macrophages and actively 
represses transcription of IL-4 (22). Absence of IFN-γ recep-
tor signaling, however, does not exclude Th1 commitment 
in EAM because CD4+ T cells from MyHC-α–immunized 
IFN-γR−/− mice were highly competent to produce IFN-γ 
upon in vitro restimulation (Fig. S1, available at http://www.
jem.org/cgi/content/full/jem.20052222/DC1). We therefore 
clarifi  ed the role of Th1 responses in EAM using mice ge-
netically defi  cient for T-bet, a T-box transcription factor es-
sential for Th1 cell lineage commitment (15). Surprisingly, 
T-bet−/− mice developed severe EAM after immunization with 
MyHC-α emulsifi  ed in CFA (Fig. 1, A and B, and Table I) 
as well as upon injection of activated MyHC-α–loaded, 
T-bet+/+ bone marrow–derived DCs (BMDCs) (Table I).
Infl  ammatory  infi   ltrates in the hearts of immunized 
T-bet+/+ and T-bet−/− mice consisted of granulocytes and 
mononuclear cells, including macrophages and lymphocytes. 
T-bet−/− hearts showed slightly greater eosinophilia and less 
fi  brosis as compared with T-bet+/+ hearts, suggesting a Th2-
biased response (not depicted). Immunohistochemical analy-
sis, however, showed no apparent diff   erences in relative 
numbers of CD68+ macrophages, CD4+ T cells, and CD8+ 
T cells between diseased T-bet−/− and T-bet+/+ hearts 
(Fig. 2). FACS analysis indicated that proportions of CD4+ 
versus CD8+ heart-infi  ltrating cells were also comparable in 
T-bet+/+ and T-bet−/− mice (not depicted).
The increase in EAM severity observed in IFN-γ−/− mice 
has been explained by impaired apoptosis of activated CD4+ 
T cells as well as by unrestricted expansion of CD4+CD44high 
T cells (23). However, we saw no evidence of impaired cell 
death in CD4+ T cells isolated from MyHC-α–immunized 
T-bet−/− mice, nor did we observe any increase in the num-
bers of peripheral CD4+CD44high cells in these mice (not de-
picted). Furthermore, most T-bet−/− mice, but none of the 
IFN-γR−/− animals, slowly recovered from disease within 
2 mo after immunization (not depicted), suggesting that loss 
of T-bet does not mimic IFN-γ defi  ciency in EAM.
T-bet−/− mice develop an autoreactive Th2 response
Consistent with the idea of CD4+ T cell–mediated disease and 
enhanced disease severity in T-bet−/− mice, in vitro recall re-
sponses of T-bet−/− CD4+ T cells to MyHC-α were increased 
in comparison with T-bet+/+ controls (Fig. 3 A). To exclude 
the possibility that T-bet does not act as a Th1 transcription 
factor in BALB/c mice, we measured IFN-γ and IL-4 
  production in T-bet−/− and T-bet+/+ CD4+ T cells. In fact, 
Figure 1.  T-bet−/− mice develop EAM of increased severity. T-bet+/+ 
and T-bet−/− mice were immunized with MyHC-α peptide in CFA 
and killed 21 d later. (A) Severity scores of individual diseased T-bet+/+ 
versus T-bet−/− mice: ***, P < 0.000001. (B) Hematoxylin and eosin–
stained sections from hearts of immunized mice. MyHC-α–immunized 
T-bet+/+ (top left), MyHC-α–immunized T-bet−/− (top right), T-bet−/− 
immunized with CFA alone (bottom left), and MyHC-α–immunized 
T-bet−/−IL-4−/−.
Figure 2.  Characterization of heart-infi  ltrating cells in T-bet−/− 
mice. Frozen heart sections from MyHC-α–immunized T-bet+/+ and 
T-bet−/− mice were stained to determine proportions of infi  ltrating mac-
rophages (CD68, right) and lymphocytes (CD4, second from left; CD8, 
second from right).JEM VOL. 203, August 7, 2006  2011
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CD4+ T cells from immunized T-bet−/− mice produced no 
IFN-γ but signifi  cant amounts of IL-4 relative to T-bet+/+ 
CD4+ T cells upon in vitro restimulation (Fig. 3 B). Further-
more, diseased T-bet−/− mice displayed a complete lack of 
myosin-specifi   c IgG2a, a Th1-dependent antibody isotype 
(Fig. 3 C). Collectively, these data indicate that Th1 diff  eren-
tiation is not required for the development of autoimmune 
myocarditis and confi   rm a Th2 phenotype of MyHC-α–
  specifi  c T-bet−/− CD4+ T cells.
EAM develops regardless of Th1 or Th2 differentiation
IL-4 is a key determinant of Th2 diff  erentiation (24). To test 
the possibility that the exaggerated production of IL-4 seen 
from T-bet−/− CD4+ T cells could increase disease severity, 
we crossed T-bet mutant mice onto IL-4– and IL-4Rα–
  defi   cient strains. Intriguingly, both T-bet−/−IL-4−/− and 
T-bet−/−IL4-Rα−/− mice developed severe EAM relative to 
T-bet+/+ and IL-4−/− or IL4-Rα−/− controls. However, dis-
ease in T-bet−/−IL-4−/− and T-bet−/−IL-4Rα−/− mice was 
comparable in severity to that seen in T-bet−/− mice (Fig. 1 B 
and Table I). This demonstrates that the exacerbated disease 
seen in T-bet−/− mice is not due to increased IL-4 signaling.
To directly examine the pathogenic role of MyHC-α–
specifi  c CD4+ T cells, we derived MyHC-α–specifi  c CD4+ 
lines from immunized T-bet−/− and T-bet+/+ mice. T-bet+/+ 
CD4+ T cell lines were skewed toward a Th1 phenotype, as 
they produced large amounts of IFN-γ, but no IL-4, upon 
restimulation. In contrast, T-bet−/− lines were Th2 skewed, 
as they produced no IFN-γ yet generated high levels of IL-4 
(Fig. 4 A). Adoptive transfer of both T-bet+/+ and T-bet−/− 
lines induced myocarditis of comparable disease severity in 
T-bet+/+ recipient mice (Fig. 4 B). These data suggest that 
EAM can develop regardless of whether Th1 or Th2 signals 
predominate in MyHC-α–specifi  c CD4+ T cells.
Table I.  Myocarditis prevalence and severity in MyHC-α–immunized mice
Mice
(genotype) Immunization
Disease prevalence
(no. diseased/no. treated) Mean score of diseased mice
T-bet−/− MyHC-α/CFA 18/18 3.56a,e,h,l,r
T-bet+/+ MyHC-α/CFA 16/19j,m 2a,b,c,d,g,k,p
IL-4−/− MyHC-α/CFA 3/4 1.67b,f
IL-4Rα−/− MyHC-α/CFA 3/4 2c,i
T-bet−/−IL-4−/− MyHC-α/CFA 4/4 3.75d,e,f
T-bet−/−IL-4Rα−/− MyHC-α/CFA 5/5 3.8g,h,i
IL-12Rβ1−/− MyHC-α/CFA 0/4j,n n.a.
IL-12p35 −/− MyHC-α/CFA 5/5 1.6k,l,q
T-bet−/−IL-12Rβ1−/− MyHC-α/CFA 0/6m,n,o n.a.
T-bet−/−IL-12p35−/− MyHC-α/CFA 6/6 3.67p,q,r
T-bet+/+ MyHC-α–pulsed T-bet+/+ DCs 4/5 1.5s,t
T-bet−/− MyHC-α–pulsed T-bet+/+ DCs 5/5 2.6s
T-bet+/+ MyHC-α–pulsed T-bet−/− DCs 3/3 1.67t
IL-12p35+/+ MyHC-α–pulsed IL-12p35+/+ DCs 4/4 1.87u
IL-12p35+/+ MyHC-α–pulsed IL-12p35−/− DCs 4/4 2.25u
Hematoxylin and eosin sections were scored as described in Materials and methods. CFA/MyHC-α–immunized mice were killed on day 21, and DC-immunized mice were killed 
on day 10. Statistical signifi  cance was assessed using the Mann-Whitney U test unless otherwise indicated. n.a., not applicable.
aP < 0.000001, T-bet−/− versus T-bet+/+.
bP < n.s, T-bet+/+ versus IL-4−/−.
cP < n.s, T-bet+/+ versus IL-4Rα−/−.
dP < 0.0008, T-bet+/+ versus T-bet−/−IL-4−/−.
eP < n.s., T-bet−/− versus T-bet−/−IL-4−/−.
fP < 0.029, IL-4−/− versus T-bet−/−IL-4−/−.
gP < 0.0002, T-bet+/+ versus T-bet−/−IL-4Rα−/−.
hP < n.s., T-bet−/− versus T-bet−/−IL-4Rα−/−.
iP < 0.036, IL-4Ra−/− versus T-bet−/−IL-4Ra−/−.
jP < 0.004, T-bet+/+ versus IL-12Rβ1−/− (Fisher’s exact test).
kP < n.s, T-bet+/+ versus IL-12p35−/−.
lP < 0.0001, T-bet−/− versus IL-12p35−/−.
mP < 0.0005, T-bet+/+ versus T-bet−/−IL-12Rβ1−/− (Fisher’s exact test).
nP < n.s, IL-12Rβ1−/− versus T-bet−/−IL-12Rβ1−/− (Fisher’s exact test).
oP < 0.000007, T-bet−/− versus T-bet−/−IL-12Rβ1−/− (Fisher’s exact test).
pP < 0.002, T-bet+/+ versus T-bet−/−IL-12p35−/−.
qP < 0.009, IL-12p35−/− versus T-bet−/−IL-12p35−/−.
rP < n.s, T-bet−/− versus T-bet−/−IL-12p35−/−.
sP < 0.0317, T-bet+/+ (T-bet+/+ DC-immunized) versus T-bet−/− (T-bet+/+ DC-immunized).
tP < n.s, T-bet+/+ (T-bet+/+ DC-immunized) versus T-bet+/+ (T-bet−/− DC-immunized).
uP < n.s., IL-12p35+/+ (IL-12p35+/+ DC-immunized) versus IL-12p35+/+ (IL-12p35−/− DC-immunized).2012  T-BET NEGATIVELY REGULATES AUTOIMMUNE MYOCARDITIS | Manu et al.
Myocarditis induction in T-bet−/− mice is IL-23 dependent
IL-12 is produced in large amounts by activated DCs and 
macrophages, and it strongly induces Th1 diff  erentiation (25). 
By inducing the up-regulation of IL-12Rβ2, T-bet can in-
crease Th1 cell sensitivity to IL-12 and thereby stabilize Th1 
lineage commitment (26, 27). In addition, IL-12p40−/− and 
IL-12Rβ1−/− mice are resistant to EAM (10, 11). However, 
IL-12 shares the p40 subunit with the related cytokine IL-23, 
and the IL-23 receptor heterodimer contains IL-12Rβ1. 
  Indeed, many of the immunological and pathogenic func-
tions initially attributed to IL-12 have now been described 
as IL-23 dependent (28). We therefore sought to examine 
whether the severe EAM that develops in the absence of 
T-bet could be regulated by either IL-12 or IL-23. We 
crossed  T-bet−/− mice onto an IL-12p35–defi  cient  strain, 
which specifi  cally lacks IL-12. IL-12p35−/− mice developed 
disease of a severity comparable to wild-type mice, whereas 
T-bet−/−IL-12p35−/− mice developed severe EAM at a level 
similar to T-bet−/− mice (Table I). DCs are a major source of 
IL-12 production (28); however, activated and MyHC-α–
pulsed IL-12p35−/− BMDCs were as capable as IL-12p35+/+ 
counterparts of inducing myocarditis in wild-type recipients 
(Table I). We then examined the eff  ect of loss of T-bet on 
an IL-12Rβ1−/− strain, which lacks both the IL-12 and the 
IL-23 receptors. Strikingly, IL-12Rβ1−/− and T-bet−/−IL-
12Rβ1−/− mice were resistant to EAM (Table I). These data 
show that IL-23, rather than IL-12, is a key pathogenic cyto-
kine in EAM. Moreover, they indicate that loss of IL-23 sig-
naling can abrogate the development of exacerbated EAM 
seen in T-bet−/− mice.
Increased IL-17 in the heart, but not peripheral lymphoid 
tissue, of immunized T-bet−/− mice
Recent fi  ndings suggest that IL-23 plays an important role in 
the expansion of an IL-17–producing subset of CD4+ T cells 
(ThIL-17) in vitro (29, 30). These cells play an essential role in 
the infectious response (31, 32) as well as in autoimmunity 
(33–35). Further data have shown that the ThIL-17 lineage is 
distinct from Th1, and that IFN-γ and T-bet can repress 
CD4+ T cell production of IL-17 (30, 35). In light of 
our fi  nding that defi  ciency in IL-23 signaling could rescue 
T-bet−/− mice from severe EAM, we examined whether in-
creased generation of ThIL-17 cells could explain the exacer-
bated disease seen in T-bet−/− mice. Restimulation of CD4+ 
T cells from both T-bet+/+ and T-bet−/− mice resulted in 
small numbers of IL-17+CD4+ T cells that were IFN-γ− 
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20052222/DC1). Despite the identifi  cation of ThIL-17 as 
a distinct CD4+ eff  ector T cell lineage, a proportion of IL-
17+ T cells can still produce IFN-γ (30). Indeed, our MyHC-
α–specifi  c, pathogenic T-bet+/+ and T-bet−/− CD4+ T cell 
lines, which produce elevated levels of IFN-γ and IL-4, re-
spectively, both secreted signifi  cant but comparable amounts 
of IL-17 (Fig. 4 A). These fi  ndings suggest that although IL-
17 production from MyHC-α–specifi  c CD4+ T cells may 
play a role in EAM in the absence of classical Th1 and Th2 
signals, T-bet does not repress the generation of such cells.
Given that IL-17 promotes the infi  ltration of neutro-
phils to local sites of infl  ammation (36), we asked whether 
heart-infi  ltrating T cells are competent to release IL-17 in 
Figure 3.  CD4+ T cell responses and cytokine production patterns 
of immunized T-bet−/− versus T-bet+/+ mice. CD4+ T cells from 
T-bet+/+ (blue bars) and T-bet−/− mice (red bars) were restimulated with 
either MyHC-α or control OVA peptide. (A) Proliferative responses after 
48 h, and (B) IFN-γ and IL-4 production in supernatants after 40 h of 
restimulation, representative of three independent experiments. (C) Serum 
MyHC-α autoantibody responses from immunized T-bet+/+ (blue) and 
T-bet−/− (red) mice at day 21. *, P < 0.05; **, P < 0.01.
Figure 4.  Th1 as well as Th2 CD4+ T cell lines trigger autoimmune 
myocarditis. (A) MyHC-α–specifi  c lines were generated by subjecting 
CD4+ splenocytes from immunized T-bet+/+ (blue) or T-bet−/− (red) mice 
to multiple rounds of antigen restimulation followed by rest in minimal 
IL-2. Supernatant was collected for ELISA 48 h after the third antigen 
restimulation. ***, P < 0.0001. One representative experiment is shown. 
(B) Both MyHC-α–specifi  c Th1 cell lines (left) and Th2 cell lines (right) are 
pathogenic in wild-type recipient mice. Hematoxylin and eosin–stained 
sections: bar: 50 μm.JEM VOL. 203, August 7, 2006  2013
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immunized mice. Surprisingly, heart-infi  ltrating CD3+ T cells 
from immunized T-bet−/− mice made signifi  cantly more IL-17 
than those taken from T-bet+/+ counterparts (Fig. 5 A). In vivo 
depletion of IL-17 in immunized T-bet−/− mice markedly 
reduced EAM severity relative to nondepleted T-bet−/− con-
trols (Fig. 5 B). These data suggest that the heightened disease 
severity seen in T-bet−/− mice may be explained by an in-
crease in T cell–mediated IL-17 production in the heart.
Normal function of T-bet−/− BMDCs and regulatory 
T (T reg) cells
Peripheral CD4+ cells from T-bet+/+– and T-bet−/−–immu-
nized mice produced comparable levels of IL-17 (Fig. S2 and 
Fig. 4). We therefore examined whether loss of T-bet in a 
diff  erent compartment might be responsible for the increase 
in EAM severity observed in T-bet−/− mice. Because T-bet 
expression is up-regulated in stimulated DCs (37, 38), we 
fi   rst evaluated the pathogenicity of activated, MyHC-α–
loaded T-bet−/− DCs using a model of DC-induced autoim-
mune myocarditis (7, 39). Stimulated and MyHC-α–pulsed 
T-bet−/− BMDCs were as pathogenic as T-bet+/+ BMDCs 
(Fig. 6 A and Table I). T-bet−/− BMDCs produced similar 
amounts of IL-6, TNF-α, and IL-12p40, and up-regulated 
MHC class II and CD80 to comparable levels, as wild-type 
controls upon in vitro stimulation (not depicted). Thus, in 
our model system of DC-induced EAM, loss of T-bet in 
DCs does not enhance autoimmune heart disease.
We next examined the potential role of T-bet in the 
maintenance of peripheral tolerance. CD4+CD25+ T reg 
cells suppress proliferation of CD4+CD25− eff  ector T cells 
in vitro and in vivo (40). Furthermore, Afanasyeva et al. 
(23) recently described impaired apoptosis of CD4+CD25+ 
T cells in IFN-γ−/− mice using the EAM model. T-bet−/− 
CD4+CD25+ T reg cells were as capable as their T-bet+/+ 
counterparts of suppressing the proliferation of CD4+CD25− 
eff  ector cells (Fig. 6 B). This data, as well as that of others 
(17), indicates that loss of T-bet does not aff  ect the suppres-
sive function of CD4+CD25+ T reg cells in vitro.
Loss of T-bet in the CD8+ compartment exacerbates EAM
Besides CD4+ T cells, CD8+ cells are also found in the heart 
infi  ltrates of diseased mice (Fig. 2), and T-bet is expressed in 
CD8+ T cells (16, 20, 41). It is unclear whether CD8+ cells 
promote or modulate EAM pathogenesis (42, 43). A direct 
pathogenic role for CD8+ T cells has been shown in trans-
genic mice expressing a class I–restricted OVA-derived pep-
tide specifi   cally in cardiomyocytes (43). In nontransgenic 
mice, however, EAM is CD4+ T cell dependent and CD8+ 
T cells do not mediate disease (7). In contrast, it appears that 
the loss of CD8+ T cells exacerbates rather than protects 
against EAM as CD8-defi   cient mice develop exacerbated 
disease (42).
We fi  rst examined the functional capabilities of T-bet−/− 
CD8+ T cells by several methods. CD8+ T cells from immu-
nized T-bet+/+ and T-bet−/− mice did not respond in vitro to ir-
radiated splenocytes pulsed with whole myosin (not depicted), 
excluding antigenic spreading to class I–restricted myosin 
  epitopes as a pathogenic mechanism. Furthermore, T-bet−/− 
CD8+ T cells mediated cytotoxic lysis of allogeneic targets to 
Figure 5.  Heart-infi  ltrating T-bet−/− CD3+ T cells display an al-
tered cytokine profi  le, and IL-17 depletion improves EAM severity 
in T-bet−/− mice. (A) Cytokine production profi  le of T-bet−/− heart-
 infi  ltrating T cells. Infi  ltrating CD3+ cells were isolated from the hearts of 
immunized T-bet+/+ (blue) or T-bet−/− (red) mice and restimulated with 
anti-CD3/anti-CD28 for 24 h. Production of indicated cytokines was as-
sessed by supernatant ELISA. *, P < 0.005. A representative of two indi-
vidual experiments is shown. (B) T-bet−/− mice were immunized with 
50 μg MyHC-α and injected with either 100 μg anti–mouse IL-17 or with 
100 μl PBS on days 9, 12, and 15. Mice were killed on day 17. Hematoxy-
lin and eosin–stained sections: bar, 200 μm. 
Figure 6.  T-bet−/− DCs and CD4+CD25+ T reg cells function nor-
mally. (A) T-bet+/+ mice were immunized with activated, MyHC-α–pulsed 
T-bet+/+ or T-bet−/− BMDCs. (B) T-bet+/+ CD4+CD25− T cells (Teff) were 
stimulated with anti-CD3 with or without T-bet+/+ or T-bet−/− CD4+CD25+ 
cells (Treg). Proliferation was measured at 72 h by [3H]thymidine incorpora-
tion. Data are representative of three independent experiments.2014  T-BET NEGATIVELY REGULATES AUTOIMMUNE MYOCARDITIS | Manu et al.
a similar degree as T-bet+/+ counterparts (Fig. S3 A, available at 
http://www.jem.org/cgi/content/full/jem.20052222/DC1).
IFN-γ has been shown to inhibit the generation of 
IL-17+ CD4+ T cells in vitro (30, 35). We therefore assessed 
the ability of T-bet−/− CD8+ T cells to produce IFN-γ. 
In agreement with previous fi  ndings (16), we found that pe-
ripheral T-bet−/− CD8+ T cells display apparently normal 
IFN-γ production upon polyclonal stimulation, regardless of 
whether they were taken from naive mice (Fig. S3 B) or from 
immunized ones (not depicted).
As  T-bet−/− heart-infi   ltrating lymphocytes produced 
  exacerbated IL-17, we examined IFN-γ production from 
T-bet+/+ and T-bet−/− T cells isolated from the hearts of immu-
nized mice. Intriguingly, we found that heart-infi  ltrating 
CD3+ T cells from immunized T-bet+/+ mice generated sub-
stantial amounts of IFN-γ when stimulated with anti-CD3/
anti-CD28, whereas heart infi  ltrating CD3+ cells from their 
T-bet−/− counterparts did not (Fig. 5 A). This fi  nding dif-
fered from the situation in the periphery: anti-CD3/anti-
CD28–stimulated splenocytes from immunized T-bet−/− 
mice could be induced to make IFN-γ (Fig. S3 C). Further-
more, heart-infi  ltrating T-bet+/+, but not T-bet−/−, CD8+ 
T cells also released IFN-γ in a TCR-independent manner 
when cultured in conditioned supernatants from LPS-
  activated BMDCs (not depicted). Importantly, CD3+CD8+, 
and not CD3+CD8−, T cells were the only heart-infi  ltrating 
cells capable of releasing IFN-γ in an antigen-independent 
manner in T-bet+/+ mice (Fig. 7 A). This fi  nding suggests 
that T cell–specifi  c production of IFN-γ in the infl  amed 
heart is restricted to the CD8+ compartment; furthermore, 
this function is T-bet dependent. Of note, we found no dif-
ferences in the production of the immunosuppressive cyto-
kines TGF-β (Fig. 5 A) and IL-10 (not depicted) between 
heart-infi  ltrating T-bet+/+ and T-bet−/− CD3+ T cells.
A role for tissue-resident CD8+ T cells in mediating non-
cognate bystander suppression has recently been described in 
a model of allergic airway infl  ammation (44). In this model, 
bystander suppression depended on IFN-γ production by 
lung resident memory CD8+ T cells. Together with the fact 
that IFN-γ negatively regulates autoimmune myocarditis 
(10, 11, 13), our fi  ndings suggest that loss of the IFN-γ–
  producing capacity of T-bet−/− CD8+ T cells might play an 
important role in the enhanced disease severity in T-bet−/− 
mice. To resolve this question in vivo, we simultaneously 
immunized SCID mice with the autoimmune MyHC-α 
peptide and reconstituted them with naive T-bet+/+ CD4+ 
cells plus either T-bet+/+ or T-bet−/− naive CD8+ cells. 
  Intriguingly, mice that received T-bet−/− CD8+ cells devel-
oped signifi  cantly more severe disease than those receiving 
T-bet+/+ CD8+ cells (Fig. 7 B and Table II). One explanation 
for these fi  ndings could be that T-bet−/− CD8+ T cells have 
a proliferative defect in vivo, thereby leading to excessive ex-
pansion of cotransferred T-bet+/+ CD4+ T cells and subse-
quently to exacerbated disease. To exclude this possibility, 
we CFSE labeled T-bet+/+ and T-bet−/− CD8+ and trans-
ferred them to SCID mice. T-bet+/+ and T-bet−/− CD8+ 
cells diluted CFSE to comparable levels upon transfer (not 
depicted), demonstrating that T-bet−/− CD8+ cells proliferate 
normally in lymphopenic hosts. Taken with the knowledge 
Figure 7.  Heart-infi  ltrating T-bet−/− CD8+ T cells display impaired 
IFN-𝗄 production, and loss of T-bet in CD8+ T cells exacerbates 
myocarditis. (A) Heart-infi  ltrating mononuclear cells from immunized 
mice were restimulated with anti-CD3/anti-CD28, stained for CD3, CD8, 
and intracellular IFN-γ, and analyzed by fl  ow cytometry. Blue boxes and 
histograms, T-bet+/+; red boxes and histograms, T-bet−/−. A representa-
tive of two individual experiments is shown. (B) SCID mice were reconsti-
tuted with either T-bet+/+ CD4+ plus T-bet+/+ CD8+ or T-bet+/+ CD4+ 
plus T-bet−/− CD8+ and immunized. Mice were killed 21 d later. Hema-
toxylin and eosin–stained sections of hearts from mice receiving T-bet−/− 
CD8+ cells (right) versus mice receiving T-bet+/+ CD8+ cells (left) are 
shown. Bars, (top) 1 mm; (bottom) 100 μm.
Table II.  Myocarditis prevalence and disease severity in SCID mice reconstituted with T-bet+/+ CD4+ T cells and T-bet+/+ versus 
T-bet−/− CD8 T cells
Recipient Reconstitution Immunization
Disease prevalence
(no. diseased/no. treated) Mean score of diseased mice
SCID T-bet+/+ CD4+ T cells MyHC-α/CFA 4/15 1a
T-bet+/+ CD8+ T cells
SCID T-bet+/+ CD4+ T cells MyHC-α/CFA 6/13  2.3a
T-bet−/− CD8+ T cells
SCID mice were reconstituted with T-bet+/+ CD4+ cells and either T-bet+/+ or T-bet−/− CD8+ cells (2:1 ratio of CD4+/CD8+). Recipients were immunized with MyHC-α at the 
time of reconstitution and killed 21 d later.
aP < 0.02 (Mann Whitney U).JEM VOL. 203, August 7, 2006  2015
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that genetic ablation of the CD8+ T cell compartment 
  exacerbates autoimmune myocarditis (42), our results demon-
strate that CD8+ T cells display down-regulatory properties 
rather than disease-promoting roles in EAM, and that these 
suppressive functions are impaired in the absence of T-bet.
In conclusion, expression of T-bet in heart-infi  ltrating 
CD8+ T cells appears critical for their ability to mediate anti-
gen-nonspecifi  c bystander suppression of local infl  ammation 
in the EAM model. This observation parallels the impaired 
release of IFN-γ and the increased production of IL-17 from 
heart-infi  ltrating T-bet−/− T cells.
DISCUSSION
To date, it has been unclear whether EAM is a Th1- or Th2-
mediated disease. Although mice lacking IL-4 signaling could 
develop EAM, the same was also true for mice defi  cient in 
IFN-γ or IFN-γR (10, 11, 13). However, our data and that 
of others (45) indicate that Th1 responses can progress in the 
absence of IFN-γ signaling. We therefore examined the de-
velopment of EAM in mice lacking the T-box transcription 
factor T-bet, which is critical for Th1 diff  erentiation (15) and 
essential for CD4+ cell tissue infi  ltration in Th1-mediated 
models of infl  ammation (46). Our fi  ndings showed that in 
sharp contrast to other autoimmune disease models (17–21, 47),
T-bet−/− mice developed EAM of exacerbated severity rela-
tive to T-bet+/+ controls. Although T-bet−/− mice were pre-
viously described to develop transiently increased disease 
severity relative to wild-type controls in a model of Staphylo-
coccus aureus–induced arthritis (48), these mice also suff  ered 
from greatly increased bacterial load, making it likely that in-
creased arthritis severity was due to impaired infectious clear-
ance rather than to autoimmune mechanisms. We therefore 
describe the fi  rst model in which T-bet negatively regulates 
autoimmune disease.
As expected, immunized T-bet−/− mice developed defec-
tive Th1 responses, as measured by the presence of MyHC-
α–specifi   c, IgG2a isotype autoantibodies and by IFN-γ 
production by restimulated CD4+ T cells. We then found 
that T-bet−/−IL-12p35−/− mice were also highly susceptible 
to EAM, excluding the possibility that IL-12 can promote 
severe Th1-driven autoimmunity in the absence of T-bet. 
At the same time, Th1- and Th2-polarized, MyHC-α–specifi  c 
CD4+ T cell lines were equally eff  ective in transferring 
  disease to healthy recipients, and both T-bet−/−IL-4−/− and 
T-bet−/−IL-4Rα−/− mice still developed severe myocarditis. 
Therefore, our results describe EAM as an autoimmune 
  disease that can develop independently of Th1/Th2 dysregu-
lation. However, we cannot exclude that Th1 or Th2 polar-
ization might contribute to the broad pattern of diff  erent 
morphologic phenotypes and clinical courses in patients with 
infl  ammatory heart disease of diff  erent causes (1, 49).
Interestingly, IL-23 signaling was absolutely required for 
EAM development, as IL-12Rβ1−/− and T-bet−/−IL-12Rβ1−/− 
mice, but not IL-12p35−/− and T-bet−/−IL-12p35−/− mice, 
were protected from disease. IL-23 is essential for the gen-
eration of IL-17–producing CD4+ T cells in vivo, and IL-17 
is a pathogenic cytokine critical for the progression of 
  experimental autoimmune encephalomyelitis (34). IL-17–
producing CD4+ T cells (ThIL-17) have been described as rep-
resenting an eff  ector cell type independent from Th1 or Th2 
cells (30, 35, 50). Although recent evidence argues against a 
role for IL-23 in the initiation of ThIL-17 diff  erentiation (51), 
it is clear that IL-23 is at least essential for the expansion 
or survival of ThIL-17 cells in vivo. We therefore examined 
whether loss of T-bet could increase IL-17 production, and 
by extension disease severity, in our EAM model. However, 
both CD4+ T cells from immunized T-bet+/+ and T-bet−/− 
mice, as well as in vitro–expanded and pathogenic MyHC-
α–specifi  c Th1 T-bet+/+ and Th2 T-bet−/− CD4+ T cell 
lines, produced comparable levels of IL-17. This suggested 
that although IL-17 production might characterize patho-
genic CD4+ T cells in EAM, T-bet did not repress IL-17 
production in the peripheral CD4+ compartment.
However, in contrast to peripheral T cells, we observed 
that IL-17 production from heart-infi   ltrating T cells was 
markedly greater in immunized T-bet−/− mice as compared 
with T-bet+/+ controls. IL-17 can act on stromal endothelial 
cells in infl  amed tissue to induce secretion of neutrophil-
  attracting factors, such as IL-8, CXCL1, and GM-CSF (36). 
This suggests that the heart-localized up-regulation of IL-17 
production in T-bet−/− mice could be pathologically relevant. 
Indeed, depletion of IL-17 in vivo markedly reduced EAM 
severity in T-bet−/− mice. Recent reports have suggested that 
loss of T-bet results in increased IL-17 production from 
CD4+ T cells in vitro (30) and from restimulated draining 
LN cells taken from MOG peptide–immunized mice (35). 
Our data strongly suggest a direct pathogenic role for IL-
17+CD4+ T cells in EAM. Furthermore, they establish for 
the fi  rst time that T-bet–mediated repression of IL-17 can 
modulate the severity of an autoimmune disease.
IFN-γ can inhibit the production of IL-17 from CD4+ T 
cells. We therefore analyzed the capacity of heart-infi  ltrating 
T cells to produce IFN-γ. In T-bet+/+ mice, heart-infi  ltrating 
CD3+CD8+, but not CD3+CD8−, cells made IFN-γ upon 
polyclonal stimulation. Intriguingly, CD8+ T cells appear to 
be responsible for almost all of the IFN-γ released within the 
diseased heart of wild-type mice in autoimmune myocarditis. 
This secretion might act to suppress local production of 
IL-17. Furthermore, CD8+ T cells from both immunized 
T-bet+/+ and T-bet−/− mice could not proliferate in response 
to whole myosin, suggesting that heart-infi  ltrating  CD8+ 
T cells in EAM secrete IFN-γ in an antigen-nonspecifi  c 
manner. Importantly, T-bet−/− heart-infi  ltrating T cells were 
wholly defi  cient in their capacity to produce IFN-γ yet were 
still able to produce other cytokines, such as TGF-β and 
TNF-α. This absence of infi  ltrating lymphocyte-specifi  c 
production of IFN-γ parallels the observed increase in IL-17 
production in T-bet−/− hearts.
Although IFN-γ has been well described as the prototypi-
cal Th1 eff  ector cytokine, it is becoming clear that it also pos-
sesses immunomodulatory properties. IFN-γ can induce APC 
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nitric oxide synthase and indoleamine-2,3-dioxygenase, and 
IFN-γ is essential for the generation of T reg cells with in 
vivo suppressive function (52). IFN-γ production is sup-
pressed in arthritic joints despite signifi  cant T cell infi  ltration, 
suggesting that local down-regulation of IFN-γ production 
contributes to autoimmune infl   ammation in rheumatoid 
  arthritis (53), and IFN-γ−/− and IFN-γR−/− mice are highly 
susceptible to severe EAM (10, 11, 13). Bystander, noncog-
nate CD8+-mediated production of IFN-γ has also been 
  implicated in the suppression of infl  ammation; CD8+ T cells 
directed against an infl  uenza-derived epitope were able to 
protect against OVA-mediated allergic airway infl  ammation 
(44). We found that although cotransfer of T-bet+/+ CD8+ 
T cells with T-bet+/+ CD4+ T cells resulted in minimal 
disease in immunized SCID recipients, transfer of T-bet−/− 
CD8+ T cells and T-bet+/+ CD4+ T cells caused signifi  cantly 
more severe EAM. These fi  ndings point toward a critical 
T-bet–dependent role of CD8+ T cells in modulating auto-
immune myocarditis severity.
Our fi   ndings that organ-infi   ltrating but not peripheral 
T-bet−/− CD8+ T cells lack the capacity to release IFN-γ 
complement recent fi  ndings that antigen-specifi  c, pancreatic 
LN–localized T-bet−/− CD8+ T cells lose the capacity to re-
lease IFN-γ and to mediate disease in the rat insulin pro-
moter–lymphocytic choriomeningitis virus transgenic model 
of autoimmune diabetes (20). In contrast to autoimmune 
myocarditis, however, the transgenic autoimmune diabetes 
model depends on a T-bet– and IFN-γ–dependent T cell re-
sponse against an MHC class I–restricted antigen. Neverthe-
less, it might be that the common defect in IFN-γ production 
by organ-infi  ltrating T-bet−/− CD8+ T cells results in impaired 
cytotoxicity in an MHC class I–restricted immune response, 
yet leads to impaired bystander suppression in an MHC class 
II–mediated disease model. We propose that the defect of 
heart-infi  ltrating T-bet−/− CD8+ T cells to release IFN-γ im-
pairs their capacity to suppress local infl  ammation in EAM.
Although we and others have found that peripheral 
T-bet−/− CD8+ T cells can produce IFN-γ, the question 
arises as to why heart-infi  ltrating CD8+ cells require T-bet 
expression to produce IFN-γ. Peripheral TCR-transgenic 
T-bet−/− CD8+ cells display defective IFN-γ production 
upon stimulation with specifi  c peptide, suggesting that upon 
strong TCR stimulation, other factors can compensate for 
the loss of T-bet in driving IFN-γ (54). Recently, the tran-
scription factor Eomes was identifi  ed as an inducer of IFN-γ 
in CD8+ T cells (54, 55). Although Eomes and other factors 
may have functions that overlap with T-bet in peripheral 
CD8+ cells, our data show that T-bet is clearly essential for 
IFN-γ production from heart-infi  ltrating CD8+ cells. It is 
possible that upon migration to the heart, CD8+ T cells un-
dergo a process of epigenetic reprogramming that renders 
T-bet essential for IFN-γ generation. Alternately, heart-in-
fi  ltrating CD8+ cells may arise from a subset of peripheral 
CD8+ T cells that absolutely require T-bet for the produc-
tion of IFN-γ. Further research is required to distinguish 
between these and other scenarios.
Clinical studies suggest that infl  ammation is a major factor 
contributing to the pathogenesis of cardiovascular diseases. 
Here we have shown that mice lacking T-bet are highly sus-
ceptible to autoimmune myocarditis. Polymorphisms in the 
gene encoding T-bet as well as its promoter have been asso-
ciated with diff  erential susceptibility to asthma in human sub-
jects (56–58). Epidemiological studies have found a signifi  cant 
association between idiopathic DCM and a history of asthma 
(59, 60), making it tempting to speculate that loss of T-bet 
may provide a common molecular mechanism underlying 
these pathologies.
Intriguingly, induction of EAM appears to be indepen-
dent of classical Th1 or Th2 eff  ector responses and is rather 
mediated by a subset of CD4+ T cells characterized by IL-17 
production. Indeed, the ablation of Th1 signaling in T-bet−/− 
mice results in severe EAM, in part by the abolition of a 
T-bet–dependent, CD8+ T cell–mediated mechanism of 
  infl  ammatory suppression. T-bet plays an essential role in 
the pathogenesis of multiple autoimmune diseases (17–21, 47) 
and has thus been proposed as a potential target of immuno-
modulatory therapy (61). However, the fi  ndings presented 
here imply that care must be taken in manipulating Th1 and 
Th2 responses in the treatment of autoimmune diseases so as 
to avoid potentially devastating side eff  ects.
MATERIALS AND METHODS
Mice. T-bet−/− mice have been described previously (62) and were a gift 
from L. Glimcher (Harvard University, Boston, MA). IL-4−/−, IL-4Rα−/−, 
IFN-γR−/−, IL-12Rβ1−/−, IL-12p35−/−, and CB17.SCID mice were pur-
chased from The Jackson Laboratory. All mice were backcrossed to the 
BALB/c strain for >10 generations and were used at 6–8 wk of age. All ex-
periments were conducted in accordance with Canadian, Austrian, or Swiss 
federal laws and institutional guidelines.
Immunization protocols. Mice were immunized with 100 μg of the 
MyHC-α peptide (MyHC-α614–634) Ac-S  L  K  L  M  A  T  L  F  S  T  Y  A  S  A  D  -OH 
emulsifi  ed 1:1 in PBS/CFA (1 mg/ml; H37Ra; Difco Laboratories) as de-
scribed previously (63). For DC immunization, BMDCs were pulsed for 2 h 
with 10 μg/ml MyHC-α peptide and stimulated for another 4 h with 0.1 
μg/ml LPS (O111:B4; Sigma-Aldrich) and 5 μg/ml anti-CD40 (BD Biosci-
ences) (7). Recipient mice received 2.5 × 105 pulsed and activated BMDCs 
i.p. for three consecutive days and were killed 10 d after the fi  rst injection. 
In IL-17 depletion experiments, mice were immunized with 50 μg MyHC-
α/CFA, injected with either anti–mouse IL-17 (R&D Systems) or PBS on 
days 9, 12, and 15, and killed on day 17.
Histopathology, immunohistochemistry, and detection of autoanti-
bodies. Myocarditis was scored on hematoxylin and eosin–stained sections 
using grades from 0 to 4: 0, no infl  ammatory infi  ltrates; 1, small foci of in-
fl  ammatory cells between myocytes; 2, larger foci of >100 infl  ammatory 
cells; 3, >10% of a cross section involved; 4, >30% of a cross section in-
volved (7). For immunohistochemistry, OCT (Sakura Finetek) - embedded 
frozen heart sections were fi  xed in acetone and processed for antibody stain-
ing according to standard protocols. The following antibodies were used: 
anti-CD4 (YTS 191), anti-CD8 (YTS 169; BD Biosciences), and anti-CD68 
(FA-11; Serotec). Autoantibody responses were determined by ELISA as 
described previously (7) using alkaline phosphatase–labeled goat anti–mouse 
IgM and IgG subclass antibodies (SouthernBiotech).
T cell functions. CD4+ and CD8+ cells were purifi  ed using magnetic 
beads (CD4+ and CD8+ T cell isolation kits; Miltenyi Biotec). 5–10 × 104 JEM VOL. 203, August 7, 2006  2017
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CD4+ T cells were restimulated for 72 h on 2 μg/ml MyHC-α peptide–
pulsed, irradiated (20 Gy) syngeneic splenocytes (2 × 105). In some experi-
ments, CD4+ or CD8+ T cells were stimulated with either 1 μg/ml each 
of plate-bound anti-CD3 and anti-CD28 (BD Biosciences) or with 1 μg/ml 
soluble anti-CD3 on 2 × 105 irradiated syngeneic splenocytes. For T reg 
cell assays, CD4+ T cells were sorted into CD4+CD25− (eff  ector T cell) 
and CD4+CD25+(T reg cell) populations using a high-speed cell sorter 
(FACSAria; BD Biosciences). 5 × 104 eff  ector T cells were cocultured with 
T reg cells on 2 × 105 irradiated syngeneic splenocytes in the presence 
or absence of 1 μg/ml soluble anti-CD3 (BD Biosciences) for 72 h. 
[3H]thymidine incorporation was measured as a readout for proliferation 
  responses. For some analyses of heart-infi  ltrating T cell cytokine produc-
tion, cells were either stimulated in the presence of soluble anti-CD3/anti-
CD28 or cultured for 72 h in supernatants from mature, LPS-stimulated 
BMDC cultures (conditioned medium). IFN-γ levels in conditioned me-
dium were always below the detection limits of our ELISA kits (<50 pg/ml). 
Cytokine levels were measured using commercially available Quantikine 
ELISA kits for detection of IFN-γ, TGF-β1, TNF-α, IL-4, IL-6, IL-10, 
IL-12p40, and IL-17 (R&D Systems). For analysis of in vivo expansion, 
CD8+ T cells were incubated for 10 min with 10 μM CFSE (Invitrogen) 
at 37°C before injection.
MyHC-𝗂–specifi  c Th1 or Th2 CD4+ lines and adoptive transfer. 
CD4+ T cells were purifi  ed from diseased T-bet+/+ or T-bet−/− mice and 
cultured with irradiated (20 Gy) splenocytes at a 1:2 ratio in the presence of 
2 μg/ml MyHC-α for 7 d. Cells were then washed and rested in the pres-
ence of 10 U/ml of recombinant IL-2 for an additional 7 d. This pulse/rest 
cycle was repeated at least three times. Finally, CD4+ T cells were restimu-
lated for 4 d before i.p. injection of 107 CD4+ T cells per syngeneic recipi-
ent. For reconstitution of SCID mice, naive CD4+ and CD8+ T cells were 
isolated and 5 × 106 CD4+ and 2.5 × 106 CD8+ T cells were injected i.p. 
into same-day immunized recipients.
FACS analysis. Cell suspensions were stained using fl  uorochrome-conju-
gated mouse-specifi  c antibodies against CD3, CD4, CD8α, CD8β, CD11c, 
CD80, MHC class II (I-Ad), CD25, IFN-γ, and IL-17. All antibodies were 
purchased from BD Biosciences. Before intracellular staining, cells were re-
stimulated for 4 h with 50 ng/ml PMA and 500 ng/ml ionomycin in the 
presence of 1 μg/ml GolgiPlug (BD Biosciences). Intracellular staining was 
conducted using the Cytofi  x/Cytoperm kit (BD Biosciences) according to 
the manufacturer’s protocols. Samples were analyzed on a FACSCalibur cell 
sorter (BD Biosciences) using Weasel (Walter and Eliza Hall Institute, 
  Melbourne, Australia) or FlowJo (TreeStar) software.
Cytotoxicity assays. T-bet+/+ and T-bet−/− (H-2d) BALB/c mice were 
primed by i.p. injection of allogeneic (H-2b) spleen-derived DCs. CD8+ T 
cells were isolated from primed mice using a biotinylated anti-CD8β anti-
body (BD Biosciences) and anti-biotin microbeads (Miltenyi Biotec). After in 
vitro   restimulation on irradiated H-2b splenocytes, cytotoxic CD8+ T cells 
were used as eff  ector cells in a calcein release assay using calcein-loaded EL-
4 H-2b target cells. Spontaneous calcein release (SR) was determined by the 
addition of medium, and maximal release (MR) was determined by the ad-
dition of lysis buff  er to target cells. Calcein release was measured after 2 h of 
incubation in a fl  uorescence multiwell plate reader (SpectraMax Gemini 
XS; Molecular Devices). Percent-specifi   c lysis was calculated as (sample 
release-SR)/(MR-SR)×100%.
Isolation of heart-infi  ltrating cells. Heart-infi  ltrating lymphocytes were 
isolated as described previously (64) with the following modifi  cations: Col-
lagenase D (Worthington Biochemical Corporation) was used at a concen-
tration of 0.895 mg/ml, and tissue suspensions were passed sequentially 
through 70- and 40-μm cell strainers (BD Falcon), and fi  nally through 15-μm 
self-assembled strainers (Sefar AG).
Statistics. The Mann-Whitney U test was used for the evaluation of sever-
ity scores. Dichotomous data were analyzed using Fisher’s exact test. Prolif-
eration responses and cytokine levels were compared using ANOVA and 
Student’s t test. Statistical analysis was conducted using Prism 4 software 
(GraphPad Software).
Online supplemental material. Fig. S1 shows that CD4+ T cells taken 
from MyHC-α–immunized IFN-γR−/− mice at day 21 are capable of pro-
ducing IFN-γ upon antigenic restimulation. Fig. S2 shows that a small 
number of CD4+ T cells from both T-bet+/+ and T-bet−/− MyHC-α–im-
munized mice develop into IL-17 producers upon antigenic restimulation. 
Fig. S3 A shows that T-bet+/+ and T-bet−/− CD8+ T cells can mediate cyto-
toxic lysis of allogeneic target cells to a comparable degree, and Fig. S3 B 
shows that naive peripheral T-bet+/+ and T-bet−/− CD8+ T cells produce 
similar levels of IFN-γ upon polyclonal stimulation. Fig. S3 C shows that 
whole splenocytes from MyHC-α–immunized T-bet−/− mice can produce 
signifi  cant, albeit reduced, levels of IFN-γ upon both antigenic and anti-
CD3/anti-CD28 restimulation.
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